Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Samankaltaisia teoksia

• Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data
  Tekijä: Kerbusch, Thomas, et al.
  Julkaistu: (2004)
• A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
  Tekijä: Gordi, Toufigh, et al.
  Julkaistu: (2005)
• Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis
  Tekijä: Wählby, Ulrika, et al.
  Julkaistu: (2004)
• Kinetics and bioavailability of two formulations of amiloride in man
  Tekijä: Smith, A. J., et al.
  Julkaistu: (1973)
• The absolute bioavailability of racemic ketamine from a novel sublingual formulation
  Tekijä: Rolan, Paul, et al.
  Julkaistu: (2014)